Neurology

Neurology

Home News Diseases Conferences Special Reports

parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia

PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

Parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia Treatment

Treatment

Surgical Intervention

Neurosurgery

Considered in patients unresponsive to pharmacological therapy

Pallidotomy

Unilateral pallidotomy has been shown to be effective in treating symptoms of dyskinesia when administered with oral Levodopa
It is unfavorable because of its irreversible nature

Deep Brain Stimulation (DBS)

Deep brain stimulation using implanted pulse generators in precise brain locations may be performed with specific indication
Both subthalamic nuclei (STN) and globus pallidus pars interna deep brain stimulation have shown efficacy in management of Parkinson's disease general/systemic motor symptoms (eg motor fluctuations, dyskinesia) when administered with oral Levodopa
Thalamic stimulation may be considered as an option in people with Parkinson's disease who predominantly have severe disabling tremor and where subthalamic nuclei stimulation cannot be performed
Good candidates for deep brain stimulation include patients whose motor symptoms are not well-controlled by medications or who cannot tolerate side effects of medications, and those who do not have significant active psychiatric or cognitive problems
Infection is the most commonly reported side effect of deep brain stimulation

Product Highlight - Pontevia

16 Mar 2022

Galcanezumab Injection

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.